Ace Therapeutics has established a comprehensive target validation and methodology development platform to facilitate the research of new diabetes-related targets and antidiabetic drug screening. We are committed to applying our expertise, advanced methods and instrumentation to provide multiple identification and validation solutions for our client's antidiabetic drug targets.

Why Target Identification for Antidiabetic Drugs is Necessary?

Identifying and validating targets and confirming their physiological and pathological importance is an extremely important part of the antidiabetic drug development phase. By identifying the targets of action of antidiabetic drugs, it is possible to gain a more in-depth understanding of the mechanism of action, predict the efficacy and safety of the drugs, and can provide guidance for the design and optimization of novel therapeutic agents. Having well-validated targets reduces the risk of late-stage failure in antidiabetic drug development.

Fig. 1 Representative antidiabetic molecular targets. (Kerru, N.; et al., 2018)

Our Target Identification Services for Antidiabetic Drugs

When conducting drug identification analyses, there are typically two scenarios to consider. The first is when there is a drug with efficacy, but the target is unknown. The second is when there is a need to find a target for new drug discovery and development. In either scenario, Ace Therapeutics can provide a full range of services related to diabetes.

Target-based Identification Services

When identifying a target for new drug discovery and development, target identification is also known as target discovery, where a druggable target needs to be established before drug screening. Ace Therapeutics provides strategies to identify genes or biomarkers with known functions in the diabetes process to develop drug screening assays. These targets typically include

• Genes associated with β-cells function.
• Metabolites, microRNAs, or other biomolecules associated with diabetes.
• Diabetes-related receptors such as insulin receptors, leptin receptors, adipokines, cytokines, etc.
• Enzymes or transporters are involved in glucose regulation or energy regulation.

We utilize a series of tests to identify new diabetes-related targets and to validate whether the target of interest can be used as a target for antidiabetic drug development. This includes:

• Targets that maintain normal function in cellular physiology.
• Targets involved in and regulating the pathophysiology of diabetes.
• Targets with localization and distribution in tissues or cells.

Phenotype-based Identification Services

When a drug exhibits efficacy but the target is unknown, target identification is also known as target deconvolution, where molecular target is determined after the drug has been proven to exert the desired effect. Phenotypic discovery is a mechanism-agnostic strategy. Therapeutics are identified by the effect upon a phenotype and subsequently the newly identified therapeutics are used to identify the mechanism of action. Ace Therapeutics is able to identify the molecular target(s) of a drug with unknown/uncertain targets but known/certain efficacy.

Features of Our Target Identification Services

Ace Therapeutics can accelerate the therapeutic development and drug discovery process about diabetes for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.

Reference

1. Kerru, N.; et al. Current antidiabetic agents and their molecular targets: A review. European Journal of Medicinal Chemistry. 152 (2018): 436-488.

• Hit Discovery Services for Antidiabetic Drugs
• Lead Discovery Services for Antidiabetic Drugs
• Lead Optimization Services for Antidiabetic Drugs

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators